BL 7040

Drug Profile

BL 7040

Alternative Names: BL7040

Latest Information Update: 27 Aug 2015

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Hebrew University of Jerusalem; Yissum Research Development Company
  • Developer BioLineRx; Ester Neurosciences
  • Class Anti-inflammatories; Oligonucleotides
  • Mechanism of Action Acetylcholinesterase inhibitors; Toll-like receptor 9 agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Phase II Ulcerative colitis
  • Discontinued Myasthenia gravis

Most Recent Events

  • 27 Aug 2015 BL 7040 is still in phase-II development for Ulcerative colitis in Israel
  • 17 Mar 2014 BL 7040 is available for licensing as of 17 Mar 2014. http://www.biolinerx.com/
  • 17 Mar 2014 Adverse events data from preclinical studies released in the BioLineRx Form 20-F
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top